Sandoz Submits Third Biosimilar Application To FDA

Law360, New York (November 18, 2015, 8:37 PM ET) -- The U.S. Food and Drug Administration has accepted a biologics license application from Novartis-owned Sandoz Inc. for a biosimilar that would help cancer patients receiving chemotherapy fight off infection, the drugmaker announced Wednesday.



The application for the biosimilar for Amgen Inc.’s Neulasta, or pegfilgrastim, comes just over two months after Sandoz launched the country's first biosimilar through the Affordable Care Act’s biosimilar pathway, known as the Biologics Price Competition and Innovation Act.



“The FDA’s acceptance of our regulatory submission for biosimilar pegfilgrastim — our third biosimilar...

To view the full article, register now.